A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 1, Phase 2
- Study design
- RANDOMIZED · SEQUENTIAL · TREATMENT · QUADRUPLE
- Evidence population
- Human clinical study registration
- Participants
- 66
- Population
- ALL · 50 Years
- Duration
- 2025-08-13 to 2029-10-01
- Intervention
- ABBV-6628; SYFOVRE
- Comparator
- Not reported
- Outcomes measured
- Number of Participants Experiencing Adverse Events — Up to approximately 25 months; Number of Participants with Abnormal Change in Physical Examinations — Up to approximately 25 months; Number of Participants with Abnormal Change From Baseline in Vital Sign Measurements — Up to approximately 25 months; Change From Baseline in Electrocardiograms (ECGs) — Up to approximately 25 months; Number of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be Assessed — Up t…; Change from baseline in Best Corrected Visual Acuity (BCVA) — Up to approximately 25 months; Change in Slit lamp biomicroscopy assessment — Up to approximately 25 months; Change in Intraocular pressure (IOP) — Up to approximately 25 months; Change in Lens examination assessment — Up to approximately 25 months; Change in Ophthalmoscopy assessment — Up to approximately 25 months; Change in fundus autofluorescence (FAF) imaging assessed by Investigator — Up to approximately 25 months; Change in Retinal evaluation — Up to approximately 25 months; Change in spectral domain optical coherence tomography (SD-OCT) — Up to approximately 25 months; Change in Fluorescein angiography (FA) assessed by Investigator. — Up to approximately 25 months; Change in choroidal neovascularization (CNV) assessed by Investigator. — Up to approximately 25 months; Percentage of Participants with Clinically Significant Post-treatment Administration Assessment (study eye only) Findin…; Maximum Serum Concentration (Cmax) of ABBV-6628 — Up to approximately 25 months; Time to Cmax (Tmax) of ABBV-6628 — Up to approximately 25 months; Area Under the Concentration-Time Curve From zero to the last measurable Timepoint (AUC0-Tlast) of ABBV-6628 — Up to ap…; Stage 2-Trough serum concentration immediately before next dose (Ctrough) of ABBV-6628 — Up to approximately 12 months
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.